Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple SclerosisEline M. E. Coerver, Eva Strijbis, Gijs Kooij et al.|JAMA Neurology|2024Cited by 29
Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS)Alyssa A Toorop, Zoé L. E. van Kempen, Zoë YGJ van Lierop et al.|Journal of Neurology Neurosurgery & Psychiatry|2023Cited by 17
Minimal clinically important difference of improvement on the Arm Function in Multiple Sclerosis Questionnaire (AMSQ)Caspar E.P. van Munster, Bernard M.J. Uitdehaag, L. Genc Kaya et al.|Multiple Sclerosis Journal|2019Cited by 13
Influence of personalized extended interval dosing on the natalizumab wearing-off effect - a sub-study of the NEXT-MS trialAlyssa A Toorop, Zoé L. E. van Kempen, Mark HJ Wessels et al.|Journal of the Neurological Sciences|2024Cited by 6
Cross-sectional and longitudinal correlations between the Arm Function in Multiple Sclerosis Questionnaire (AMSQ) and other outcome measures in multiple sclerosisPam C. G. Molenaar, Nynke F. Kalkers, Eva Strijbis et al.|Multiple Sclerosis and Related Disorders|2022Cited by 5